27 Dec 2019 07:00
27 December 2019
NMC Health plc
(the "Company" or "NMC")
Independent confirmation of built-up floor area of NMC Royal Women's Hospital
NMC Health plc (LSE: NMC) announces that, further to the Company's statement on 19 December 2019, it has obtained a letter from STH Consultant, the Engineering Consultant retained for the NMC Royal Women's Hospital (formerly Brightpoint Hospital) development project, confirming the total built-up floor area of the hospital at 18,595 sqm. The Company has also made available HAAD (Health Authority of Abu Dhabi) approved floor plans of NMC Royal Women's Hospital. Both documents are available in the Shareholder Information section of the Company's Investor Relations page (please see: https://nmc.ae/investorrelations/shareholderinformation).
Contacts
NMC |
|
Asjad Yahya, Investor Relations | +971 (0)56 219 0975 |
|
|
Media |
|
FTI Consulting, London |
|
Edward Bridges /Simon Conway / Victoria Foster Mitchell | +44 (0)20 3727 1000 |
|
|
FTI Consulting, Gulf |
|
Shane Dolan | +971 (0)4 437 2100 |
About NMC Health
NMC is one of the leading private healthcare operators in the Gulf Cooperation Council ("GCC") with an international network of multi-specialty inpatient and outpatient clinics and hospitals, specialized maternity and fertility clinics, and long-term care homes hospitals across nineteen countries. NMC also ranks as one of the top two in-vitro fertilisation operators globally. The NMC Health group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing a selective international expansion programme since 2016, NMC has total capacity of 2,207 licensed beds across its network. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region's largest healthcare market. The NMC Health group treated over 7.5 million patients in 2018. The NMC Health group is also a leading UAE supplier of products and consumables coming from healthcare related products. NMC reported revenues of US$2.1 billion for the year ended 31 December 2018.
In April 2012, NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 100 Index.